Yes and I think Power is making an assumption that Donepezil hinders or reduces the positive effect that A2-73 might have.
This has been considered by Anavex and found not to be the case. Now in more than one trial: AD P2a, PDD P2 and Dzp continuing to be allowed in the OLE trial as well as. Despite the protests, also in the P2b/3 AD trial.
The bias even internally on the Anavex sacred research is astounding, those results that say nice things must be accepted as literal truth, whereas other finding published by Anavex are deemed wrong because they don't fit with a hobby horse belief.
Market Data 
Markets 
AI
